Total Payments
$4,724
2024 Payments
$4,605
Companies
2
Transactions
25
Medicare Patients
456
Medicare Billing
$39,040
Payment Breakdown by Category
Research$4,605 (97.5%)
Food & Beverage$119.38 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4,605 | 24 | 97.5% |
| Food and Beverage | $119.38 | 1 | 2.5% |
Payments by Type
Research
$4,605
24 transactions
General
$119.38
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| RECORDATI_RARE_DISEASES_INC. | $4,605 | 24 | $0 (2024) |
| Amgen Inc. | $119.38 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,605 | 24 | RECORDATI_RARE_DISEASES_INC. ($4,605) |
| 2017 | $119.38 | 1 | Amgen Inc. ($119.38) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $365.75 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 10/25/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $136.33 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 10/25/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $136.33 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 10/18/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $112.50 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 09/04/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $272.65 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 08/02/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $272.65 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 07/08/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $225.00 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 07/08/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $187.50 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/06/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $365.75 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/06/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $34.08 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/06/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $34.08 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/06/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $34.08 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/06/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $34.08 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/06/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $34.08 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/06/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $34.08 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/06/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $34.08 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/06/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $34.08 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 03/05/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $225.00 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 02/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $1,100.00 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 02/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $225.00 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 02/09/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $162.50 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 01/26/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $272.65 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 01/03/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $136.33 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 01/03/2024 | RECORDATI_RARE_DISEASES_INC. | OSILODROSTAT (Drug) | — | Cash or cash equivalent | $136.33 | Research |
| Study: LCI699-RECAG-PASS-0572 • Category: ENDOCRINE AGENT | ||||||
| 06/21/2017 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $119.38 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LCI699-RECAG-PASS-0572 | RECORDATI_RARE_DISEASES_INC. | $4,605 | 24 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 74 | 91 | $27,925 | $6,597 |
| 2022 | 3 | 100 | 126 | $33,713 | $8,562 |
| 2021 | 4 | 148 | 192 | $45,911 | $13,008 |
| 2020 | 5 | 134 | 159 | $36,981 | $10,873 |
Total Patients
456
Total Services
568
Medicare Billing
$39,040
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 46 | 58 | $17,530 | $4,069 | 23.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 17 | 22 | $6,108 | $1,453 | 23.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $4,287 | $1,075 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 47 | 65 | $16,917 | $4,452 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 20 | 24 | $6,184 | $1,684 | 27.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 20 | 24 | $5,944 | $1,252 | 21.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $4,668 | $1,174 | 25.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 62 | 90 | $20,952 | $6,366 | 30.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 29 | 40 | $9,140 | $2,946 | 32.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 14 | 14 | $4,771 | $1,194 | 25.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 14 | 14 | $4,776 | $980.62 | 20.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 17 | 19 | $4,009 | $779.66 | 19.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 12 | 15 | $2,263 | $741.53 | 32.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 50 | 71 | $14,382 | $4,093 | 28.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 18 | 18 | $5,976 | $1,709 | 28.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 16 | 16 | $5,312 | $1,657 | 31.2% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 11 | 11 | $2,948 | $1,029 | 34.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 13 | 15 | $3,310 | $985.89 | 29.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 14 | 15 | $3,042 | $887.10 | 29.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 12 | 13 | $2,011 | $512.98 | 25.5% |
About Dr. Elena Varlamov, MD
Dr. Elena Varlamov, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2012. The National Provider Identifier (NPI) number assigned to this provider is 1669731204.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Elena Varlamov, MD has received a total of $4,724 in payments from pharmaceutical and medical device companies, with $4,605 received in 2024. These payments were reported across 25 transactions from 2 companies. The most common payment nature is "" ($4,605).
As a Medicare-enrolled provider, Varlamov has provided services to 456 Medicare beneficiaries, totaling 568 services with total Medicare billing of $39,040. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Portland, OR
- Active Since 05/15/2012
- Last Updated 08/04/2017
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1669731204
Products in Payments
- OSILODROSTAT (Drug) $4,605
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Portland
Mr. Michael Mcclung, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1.6M
Endocrinology, Diabetes & Metabolism $1.6M
James Neifing, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $475,019
Endocrinology, Diabetes & Metabolism $475,019
Maria Fleseriu, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $418,716
Endocrinology, Diabetes & Metabolism $418,716
Rodica Busui, Md, Phd, MD, PHD
Endocrinology, Diabetes & Metabolism — Payments: $211,479
Endocrinology, Diabetes & Metabolism $211,479
Jonathan Purnell, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $209,631
Endocrinology, Diabetes & Metabolism $209,631
Nancy Curosh, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $194,307
Endocrinology, Diabetes & Metabolism $194,307